Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 16,393 Shares

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the sale, the general counsel now directly owns 573,478 shares in the company, valued at $6,755,570.84. This trade represents a 2.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, December 2nd, Russell Schundler sold 1,063 shares of Liquidia stock. The stock was sold at an average price of $11.51, for a total transaction of $12,235.13.

Liquidia Trading Down 3.4 %

LQDA traded down $0.40 during trading on Tuesday, hitting $11.36. 552,977 shares of the company’s stock were exchanged, compared to its average volume of 728,753. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.99. The stock has a 50 day moving average price of $11.18 and a 200 day moving average price of $11.02. The firm has a market cap of $961.48 million, a P/E ratio of -6.97 and a beta of 0.23.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price for the company. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Scotiabank assumed coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of Liquidia in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $25.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its holdings in Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after acquiring an additional 123,402 shares in the last quarter. Whitefort Capital Management LP increased its holdings in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after acquiring an additional 927,546 shares during the period. Charles Schwab Investment Management Inc. grew its position in Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. Barclays PLC grew its position in Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after buying an additional 72,591 shares in the last quarter. Finally, Sapient Capital LLC bought a new position in Liquidia in the 3rd quarter valued at about $1,336,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).